Program
BAY 3389934
A development code. Also written as “BAY3389934”.
Its studies are mostly in Sepsis, led by Bayer.
Furthest: phase 1, since Feb 28, 20253 company-led studies, 2 open or runningNext primary completion: Dec 25, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 32 open or running | phase 1since Feb 28, 2025 | Feb 28, 2025 | Dec 25, 2026phase 1 · NCT06854640 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 28, 2025First study: phase 1 study in SepsisFirst studyNCT06854640 · 36 planned · United States, Belgium, France and more
- Aug 29, 2025Phase 1 study in SepsisNCT07176728 · 16 enrolled · Japan
- Jun 8, 2026Phase 1 study in Drug-drug InteractionNCT07652723 · 16 planned · United States
Ahead
- Dec 25, 2026Primary completion: phase 1 study in SepsisNCT06854640
- Mar 10, 2027Primary completion: phase 1 study in Drug-drug InteractionNCT07652723
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07652723Drug-drug Interaction · United States | 1 | Recruiting | Mar 10, 2027 | 16 |
| NCT07176728Sepsis · Japan | 1 | Completed | May 17, 2026 | 16 |
| NCT06854640Sepsis · United States, Belgium, France and more | 1 | Recruiting | Dec 25, 2026 | 36 |
How it is read
Names in the registry
- “BAY3389934”, 2 entries
- “BAY 3389934”, 1 entry
Codes read as this program: BAY3389934.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.